Amneal Pharmaceuticals, Inc. (AMRX)
Stock Price Chart
Key Info
| Market Cap | 1.31B |
| Revenue (ttm) | 1.68B |
| Net Income (ttm) | -198.97M |
| Shares Out | 147.31M |
| EPS (ttm) | -1.46 |
| PE Ratio | n/a |
| Forward PE | 8.87 |
| Dividend | n/a |
| Dividend Yield | n/a |
Stock Quote
| Trading Day | Jul 9, 2020 |
| Last Price | $4.38 |
| Previous Close | $4.51 |
| Change ($) | -0.14 |
| Change (%) | -2.99% |
| Day's Open | 4.51 |
| Day's Range | 4.30 - 4.55 |
| Day's Volume | 459,555 |
| 52-Week Range | 2.27 - 6.89 |
More Stats
| Market Cap | 1.31B |
| Enterprise Value | 4.18B |
| Earnings Date (est) | Aug 6, 2020 |
| Ex-Dividend Date | n/a |
| Shares Outstanding | 147.31M |
| Float | 94.10M |
| EPS (basic) | -1.56 |
| EPS (diluted) | -1.46 |
| FCF / Share | 0.83 |
| Dividend | n/a |
| Dividend Yield | n/a |
| Earnings Yield | n/a |
| FCF Yield | 9.36% |
| Payout Ratio | n/a |
| Shares Short | 5.83M |
| Short Ratio | 3.31 |
| Short % of Float | 7.05% |
| Beta | 1.68 |
| PE Ratio | n/a |
| Forward PE | 8.87 |
| P/FCF Ratio | 10.69 |
| PS Ratio | 0.78 |
| PB Ratio | 4.25 |
| Revenue | 1.68B |
| Operating Income | -96.53M |
| Net Income | -198.97M |
| Free Cash Flow | 122.58M |
| Net Cash | -2.87B |
| Net Cash / Share | -9.58 |
| Gross Margin | 29.60% |
| Operating Margin | -5.75% |
| Profit Margin | -11.90% |
| FCF Margin | 7.30% |
| ROA | 1.35% |
| ROE | -58.78% |
| ROIC | 6.00% |
Analyst Summary
Analyst Consensus: Overweight
Financial Performance
Financial Overview
| Year | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 |
|---|---|---|---|---|---|---|
| Revenue | 1,626 | 1,663 | 1,034 | 1,018 | 860 | 786 |
| Revenue Growth | -2.2% | 60.88% | 1.52% | 18.33% | 9.53% | - |
| Gross Profit | 353 | 716 | 526 | 597 | 352 | 448 |
| Operating Income | -249 | -19.67 | 245 | 285 | 69.57 | 219 |
| Net Income | -362 | -20.92 | - | - | 39.00 | 177 |
| Shares Outstanding | 132 | 127 | 71.86 | 71.15 | 69.64 | - |
| Earnings Per Share | -2.74 | -0.16 | -6.53 | -6.63 | 0.54 | - |
| Operating Cash Flow | 1.71 | 250 | 234 | 115 | 92.45 | 112 |
| Capital Expenditures | -47.18 | -57.74 | -94.77 | -123 | -25.20 | -79.38 |
| Free Cash Flow | -45.48 | 192 | 139 | -7.70 | 67.25 | 32.87 |
| Cash & Equivalents | 153 | 219 | 77.92 | 180 | 65.11 | 0.00 |
| Total Debt | 2,766 | 2,691 | 1,485 | 831 | 1,012 | - |
| Net Cash / Debt | -2,613 | -2,473 | -1,407 | -651 | -947 | 0.00 |
| Assets | 3,666 | 4,353 | 1,342 | 1,823 | 1,014 | - |
| Liabilities | 3,319 | 3,456 | 1,717 | 1,199 | 1,201 | - |
| Book Value | 232 | 505 | -386 | 624 | -195 | - |
Company Profile
Company Details
| Full Name | Amneal Pharmaceuticals, Inc. |
| Country | United States |
| Employees | 5,500 |
| CEO | Chintu Patel / Chirag K. Patel |
Stock Information
| Ticker Symbol | AMRX |
| Stock Exchange | New York Stock Exchange |
| Sector | Healthcare |
| Industry | Drug Manufacturers—Specialty & Generic |
| Unique Identifier | NYSE: AMRX |
Description
Amneal Pharmaceuticals, Inc., together with its subsidiaries, develops, licenses, manufactures, markets, and distributes generic and specialty pharmaceutical products for various dosage forms and therapeutic areas. The company operates in two segments, Generics and Specialty. The Generics segment develops, manufactures, and commercializes complex oral solids, injectables, ophthalmics, liquids, topicals, softgels, inhalation products, and transdermals across a range of therapeutic categories. The Specialty segment is involved in the development, manufacture, and sale of branded pharmaceutical products primarily for central nervous system disorders, endocrinology, parasitic infections, and other therapeutic areas. It also offers licensed and owned, niche, and mature branded products, as well as Rytary for the treatment of Parkinsons Disease; Zomig for the treatment of migraine headaches; Emverm a chewable tablets for the treatment of pinworm, whipworm, common roundworm, common hookworm, and American hookworm in single or mixed infections; and Unithroid for the treatment of hypothyroidism. The company sells its products through wholesalers, distributors, hospitals, chain pharmacies, and individual pharmacies. It has operations in the United States, India, Ireland, and internationally. The company was formerly known as Atlas Holdings, Inc. and changed its name to Amneal Pharmaceuticals, Inc. in 2018. Amneal Pharmaceuticals, Inc. was founded in 2002 and is based in Bridgewater, New Jersey.